Research Use Only - Not for human consumption. 18+ only.
DGrade DTheoretical or in-vitro only; no meaningful independent human evidenceResearch OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use onlySpecialized PeptidesSubcutaneous

Adipotide

Also known as: FTPP, Prohibitin-TP01

An experimental peptidomimetic that targets and destroys fat tissue blood supply through a targeted proapoptotic peptide. Causes fat cell death by cutting off blood supply to adipose tissue.

Beginner Basics

Plain-English guide to Adipotide

What it does

This experimental peptide works by cutting off the blood supply to fat cells, which causes them to die and shrink. Researchers study it because it targets fat tissue directly, especially deep belly fat, and may help improve how the body processes energy.

Typical dose

Research typically uses 0.5-1 mg once daily, injected under the skin. Important note: this is based on animal studies only-human dosing is completely unknown.

When to inject

No specific time requirement. Inject once daily at whatever time is convenient for you.

Storage

Keep the dry powder in the freezer at -20°C. Once you mix it with liquid, store it in the refrigerator between 2-8°C and keep it away from direct light.

First-timer tip

This peptide is still experimental with documented safety concerns and has never been tested in humans-understand the significant risks before using, and consider starting at the lower end of the dose range if you proceed.

Research Status

DGrade DTheoretical or in-vitro only; no meaningful independent human evidenceResearch OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only

Early Research

For research purposes only. Not approved for human use. Not medical advice.

Research Areas

Reduces adipose tissue mass
Targets visceral fat deposits
Induces selective fat cell apoptosis
May improve metabolic markers

Side Effects

Acute kidney injury
CommonSerious

Documented in preclinical studies at therapeutic doses. Manifests as elevated serum creatinine and blood urea nitrogen. Mechanism may involve vascular disruption in renal tissue or direct endothelial toxicity. Requires immediate medical evaluation and discontinuation.

Hepatotoxicity
CommonSerious

Elevated liver enzymes (ALT, AST) observed in animal studies. Potential mechanism involves off-target vascular effects in hepatic tissue. Requires liver function monitoring and medical evaluation.

Injection site reactions
UncommonMild

Local erythema, induration, or mild pain at injection site. Typically resolves within 24-48 hours. Rotate injection sites to minimize recurrence.

Fatigue
UncommonMild

May occur due to rapid metabolic changes or systemic effects. Usually mild and self-resolving.

Nausea
UncommonMild

Reported in some preclinical studies. Typically mild and transient.

Vascular complications
RareSerious

Potential for off-target vascular effects in tissues other than adipose tissue. Risk of thrombosis, hemorrhage, or ischemic injury to vital organs. Requires immediate medical attention.

Coagulopathy
UncommonSerious

Vascular disruption may trigger abnormal clotting. Requires hematologic monitoring and medical evaluation.

Dosing Reference

ParameterValue
Dose range0.5-1 mg
Frequency, timing and route - members only

Research disclaimer

Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.

Reconstitution Guide

Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution

Do not shake the vial vigorously; gentle swirling prevents peptide degradation

Discard immediately if the solution appears cloudy, discolored, or contains visible particles

Use within 30 days of reconstitution when stored at 2-8°C

Do not freeze the reconstituted solution; freezing may denature the peptide

Use the PeptideVolt reconstitution calculator for your exact concentration

Use the PeptideVolt reconstitution calculator for your exact concentration

Molecular and Pharmacological Data

Adipotide is a peptidomimetic that targets the vasculature of adipose tissue through a proapoptotic mechanism. The peptide binds to integrin receptors on endothelial cells within fat tissue blood vessels, triggering apoptosis (programmed cell death) of these vascular cells. This vascular disruption cuts off blood supply to adipocytes, leading to selective fat cell death and reduction of adipose tissue mass.

Pathways and mechanism detail available to members

Track your Adipotide research

Free account. No credit card required.

Start Free

Browse the Research Library

40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.

View all peptides

Research Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Adipotide is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.